YH ENT (02306) fell over 4% again, with its shares now down more than 40% from this year's peak. At the time of writing, the stock dropped 4.37% to HK$1.97, with a trading volume of HK$2.72 million.

Market attention has turned to the renewal of Wang Yibo's contract after related hashtags like "Wang Yibo not renewing with YH ENT" trended on Weibo. According to reports, YH ENT's investor relations department stated, "His (Wang Yibo's) revenue contribution to the company is gradually declining, and his contract is originally set to expire next year. Please refer to our official announcement at that time."

Wang Yibo's contract with YH ENT is due to expire in October 2026, and any changes in their partnership are being closely watched. YH ENT's disclosures show that Wang Yibo contributed 16.8% of total revenue in 2019, but this figure rose to 59% in the first three quarters of 2022. In 2024, YH ENT reported total revenue of RMB765 million, with Wang Yibo accounting for RMB459 million, or over 60%.